Rucaparib (Rubraca)


Indications for Prior Authorization:

  • for use as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies

Patients must meet the following criteria for the indication(s) above:

  • Diagnosis of deleterious germline BRCA mutations confirmed by genetic testing

  • Patient has prior history of treatment with at least 2 chemotherapy regimens
  • Females of reproductive potential: pregnancy testing prior to treatment initiation and use of contraception during therapy and for 6 months after the last dose
  • Continuation allowed until disease progression or unacceptable toxicity

The following conditions do not meet the criteria for use as established by WHA P&T committee:

  • All non-FDA approved uses not listed in the approved indications


  • 600mg (two 300mg tablets) orally twice daily


  • Initial approval: 2 months

  • Renewal: 6 months


Last review date: March 22, 2017

WHA is closely monitoring the Coronavirus Disease 2019 (COVID-19). Learn more about COVID-19.